LPL Financial’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$550K Buy
203,746
+56,000
+38% +$104K ﹤0.01% 4937
2026
Q1
$177K Buy
147,746
+2,930
+2% +$3.57K ﹤0.01% 5542
2025
Q4
$142K Buy
144,816
+120,900
+506% +$145K ﹤0.01% 5538
2025
Q3
$30.1K Buy
23,916
+10,000
+72% +$10.8K ﹤0.01% 5697
2025
Q2
$15.6K Sell
13,916
-76,599
-85% -$89K ﹤0.01% 5497
2025
Q1
$71.5K Buy
90,515
+17,395
+24% +$21.3K ﹤0.01% 5101
2024
Q4
$121K Buy
+73,120
New +$184K ﹤0.01% 4952
2021
Q4
Sell
-3,444
Closed -$204K 4378
2021
Q3
$204K Buy
3,444
+609
+21% +$47.8K ﹤0.01% 3969
2021
Q2
$246K Buy
+2,835
New +$228K ﹤0.01% 3752

Other funds holding FATE

LPL Financial's FATE Position: Q2 2026 in Review

LPL Financial increased its Fate Therapeutics (FATE) stake by 38% in Q2 2026, buying an estimated $104K and bringing the position to 203,746 shares worth $550K. The position accounts for ﹤0.01% of the portfolio, ranked #4937.

LPL Financial first reported a position in FATE in Q2 2021 and has held it in 9 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • LPL Financial held 203,746 shares of Fate Therapeutics worth $550K as of Q2 2026.
  • LPL Financial bought 56,000 Fate Therapeutics shares in Q2 2026, an estimated $104K.
  • Fate Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #4937 holding.
  • LPL Financial first reported a position in Fate Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.